Voveran Emulgel 1.16% (India)
Voveran Emulgel 1.16% (India)
$35.59
Earn 2 points upon purchasing this product.
30g
Requires Prescription
SKU: 79442 Categories: Arthritis Medications/Gout Medications, Generic, India, Prescription Drugs, VoltarenUses of Voveran Emulgel 1.16%
Administer Voveran Emulgel 1.16% to treat conditions like migraines, rheumatoid arthritis, muscle spasms, and Gout. This prescription medicine is a non-steroidal anti-inflammation medication that works by inhibiting the formation of chemical messengers that cause swelling and pain in the body. Voveran Emulgel 1.16% is a topical medication that relieves pain associated with osteoarthritis.
Voveran Emulgel Warnings and Precautions
Do not use Voveran Emulgel 1.16% if you are allergic to it. Use this topical medication as directed by the healthcare professional. Avoid direct contact with eyes or open wounds.
Before using Voveran Emulgel 1.16%, tell your healthcare professional if you have a history of the following conditions:
- Asthma
- Impaired kidney function
- Cardiovascular problems
Voveran Emulgel Dosage
Healthcare professionals recommend using Voveran Emulgel 1.16%, 3-4 times a day to achieve the full benefits of this medicine.
Apply Voveran Emulgel directly to the affected area. Stick to the instructions provided by your healthcare professional, especially the dosage recommended. To ensure maximum efficiency, gently rub the gel after applying it.
Avoid applying the gel to damaged skin to prevent further damage or conditions.
Voveran Emulgel Side Effects
Common side effects:
- Abdominal pain
- Heartburn
- Rashes
- Skin redness
- Tingling sensation
- Inflammation
- Itching
- Dizziness
- Scaling
- Numbness
Only logged in customers who have purchased this product may leave a review.
Cart
Product Search
Product Categories
Top Rated Products
-
Abilify 2mg
$129.89
-
Osteofos 70mg (India)
$43.91
-
Arnuity Ellipta Inhaler 100mcg
$64.99
-
Nebistar 2.5mg (India)
$42.99
-
Tadalafil 2.5mg
$69.99
-
Combigan 0.2/0.5% (Turkey)
$32.37
Reviews
There are no reviews yet.